BioCentury | May 30, 2020
Translation in Brief

Empirica’s glioblastoma CAR T therapy in mice; plus tumor microbiomes by tumor type, Senhwa and more

Brain cancer CAR T therapy  A McMaster University and University of Toronto team revealed in a Cell Stem Cell paper proof-of-concept data for Empirica Therapeutics’ lead product eCAR-133, a CAR T cell therapy targeting PROM1....
BioCentury | May 6, 2020

FDA approval of Novartis’ capmatinib heralds arrival of new targeted lung cancer therapies

FDA’s approval of the c-MET inhibitor Tabrecta capmatinib from Novartis is the first for a series of targeted non-small cell lung cancer therapies expected to reach the market this year. It’s also the first approval...
BioCentury | May 4, 2020
Product Development

Investors see little value in remaining Newron programs following Rett syndrome failure

The failure of Newron’s sarizotan in Rett syndrome leaves the company with two pipeline programs, but its valuation is now trading near its cash position -- a sign that investors see little value in what...
BioCentury | May 2, 2020
Product Development

Daily Chart: Oxford’s global network of COVID-19 vaccine manufacturing sites

To meet demand as much demand for its COVID-19 vaccine as quickly as possible, the University of Oxford has been building a coalition of manufacturing partners before it even knows if the vaccine works. The...
BioCentury | Apr 30, 2020

AstraZeneca to make COVID-19 vaccine with roots in Oxford’s CEPI-funded MERS project

When the first therapies and vaccines for COVID-19 are approved, it is likely that they will be the result of responses to prior viral outbreaks and pandemic preparedness programs. Products that will be hailed as...
BioCentury | Apr 29, 2020
Product Development

India emerging as major COVID-19 vaccine manufacturer

At least six Indian companies are developing or co-developing COVID-19 vaccines, but India’s biggest contribution to fighting the pandemic is likely to come from its manufacturing might. The Serum Institute of India, the world’s largest...
BioCentury | Apr 29, 2020
Product Development

Pfizer joins front of pack in COVID-19 vaccine race

A COVID-19 vaccine from BioNTech and Pfizer could be available for emergency use by October -- several months ahead of a J&J vaccine and just off the pace of vaccines from Oxford’s Jenner Institute and...
BioCentury | Apr 24, 2020
Emerging Company Profile

FoRx: A broader look at DNA damage repair

University of Geneva spinout FoRx debuted this week with €10 million in seed funding, a trio of strategic investors, and a new approach to synthetic lethality that could expand the cancer-killing mechanism to a broad...
BioCentury | Apr 24, 2020
Product Development

Sanofi sets MS submission goals for Principia-partnered Btk inhibitor, details Phase II data

Two months after Sanofi announced plans to send its oral multiple sclerosis therapy into Phase III testing, the company unveiled the detailed Phase IIb data from recurring MS patients driving the Btk inhibitor’s clinical advancement....
BioCentury | Apr 23, 2020
Product Development

April 22 Quick Takes: Accelerated approval for Immunomedics’ Trodelvy; plus BioNTech-Pfizer, AskBio, Astellas, Merck KGaA, oNKo-Gilead, Myovant, Afyx and Sangam

Immunomedics’ Trodelvy approved for TNBC  FDA granted accelerated approval to Trodelvy sacituzumab govitecan from Immunomedics Inc. (NASDAQ:IMMU) for adult metastatic triple-negative breast cancer patients in the third-line setting. Immunomedics said continued approval of the TROP2-targeting...
Items per page:
1 - 10 of 2557